Department of Nuclear Medicine and PET Centre, Aarhus University Hospital, Aarhus, Denmark.
J Nucl Med. 2014 Apr;55(4):590-4. doi: 10.2967/jnumed.113.125559. Epub 2014 Mar 3.
The galactose analog 2-(18)F-fluoro-2-deoxy-d-galactose ((18)F-FDGal) is a suitable PET tracer for measuring hepatic galactokinase capacity in vivo, which provides estimates of hepatic metabolic function. As a result of a higher affinity of galactokinase toward galactose, the lumped constant (LC) for (18)F-FDGal was 0.13 in healthy subjects. The aim of the present study was to test the hypothesis of a significantly different LC for (18)F-FDGal in patients with parenchymal liver disease.
Nine patients with liver cirrhosis were studied in connection with a previous study with determination of hepatic intrinsic clearance of ¹⁸F-FDGal (V*(max/K*(m)). The present study determined the hepatic removal kinetics of galactose, including hepatic intrinsic clearance of galactose (V(max)/K(m)) from measurements of hepatic blood flow and arterial and liver vein blood galactose concentrations at increasing galactose infusions. LC for ¹⁸F-FDGal was calculated as (V*(max)/K*(m))/(V(max)/K(m)). On a second day, a dynamic ¹⁸-FDGal PET study with simultaneous infusion of galactose (mean arterial galactose concentration, 6.1 mmol/L of blood) and blood samples from a radial artery was performed, with determination of hepatic systemic clearance of ¹⁸F-FDGal (K*(+gal) from linear analysis of data (Gjedde-Patlak method). The maximum hepatic removal rate of galactose was estimated from ¹⁸F-FDGal PET data (V(max)(PET)) using the estimated LC.
The mean hepatic V(max) of galactose was 1.18 mmol/min, the mean K(m) was 0.91 mmol/L of blood and the mean V(max)/K(m) was 1.18 L of blood/min. When compared with values of healthy subjects, K(m) did not differ (P = 0.77), whereas both V(max) and V(max)/K(m) were significantly lower in patients (both P < 0.01). Mean LC for ¹⁸LF-FDGal was 0.24, which was significantly higher than the mean LC of 0.13 in healthy subjects (P < 0.0001). Mean K*(+gal) determined from the PET study was 0.019 L of blood/min/L of liver tissue, which was not significantly different from that in healthy subjects (P = 0.85). Mean hepatic V(max)(PET) was 0.57 mmol/min/L of liver tissue, which was significantly lower than the value in healthy subjects (1.41 mmol/min/L of liver tissue (P < 0.0001).
Disease may change the LC for a pet tracer, and this study demonstrated the importance of using the correct LC.
本研究旨在检验这样一种假设,即实质肝疾病患者的(18)F-FDGal 有显著不同的 LC。
9 例肝硬化患者参与了先前的研究,以测定 ¹⁸F-FDGal 的肝内在清除率(V*(max/K*(m))。本研究通过测量肝血流量和递增的半乳糖输注时的肝动脉和肝静脉血中半乳糖浓度,从测量中确定了半乳糖的肝清除动力学,包括半乳糖的肝内在清除率(V(max)/K(m))。在第二天,进行了 ¹⁸F-FDGal 的动态 PET 研究,同时输注半乳糖(平均动脉半乳糖浓度为 6.1mmol/L 的血液)和来自桡动脉的血液样本,并通过线性分析(Gjedde-Patlak 法)确定 ¹⁸F-FDGal 的肝全身清除率(K*(+gal))。从 ¹⁸F-FDGal PET 数据(V(max)(PET))中使用估计的 LC 来估计半乳糖的最大肝清除率。
半乳糖的平均肝 V(max)为 1.18mmol/min,平均 K(m)为 0.91mmol/L 的血液,平均 V(max)/K(m)为 1.18L/min。与健康受试者的值相比,K(m)没有差异(P=0.77),而 V(max)和 V(max)/K(m)在患者中均显著降低(均 P<0.01)。¹⁸LF-FDGal 的平均 LC 为 0.24,明显高于健康受试者的平均 LC(0.13)(P<0.0001)。从 PET 研究中确定的平均 K*(+gal)为 0.019L/min/L 的肝组织,与健康受试者没有显著差异(P=0.85)。平均肝 V(max)(PET)为 0.57mmol/min/L 的肝组织,明显低于健康受试者(1.41mmol/min/L 的肝组织)(P<0.0001)。
疾病可能会改变 PET 示踪剂的 LC,本研究证明了使用正确 LC 的重要性。